Benzinga · Mar 26, 2026
HC Wainwright & Co. Maintains Buy on Insmed, Raises Price Target to $245
HC Wainwright & Co. analyst Andrew S. Fein maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $230 to $245.
IN
NASDAQ · INSM
Insmed Incorporated
Healthcare · Medical - Pharmaceuticals
$118.54
Up+$1.31 (+1.11%)
Updated Aug 31, 2026, 3:00 PM
SID Score
6.2/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 41.63B
- P/E ratio
- -34.92
- Dividend yield
- 0.00%
- 52-week range
- $90.39 – $212.75
- Volume
- 1.98M
- Avg. volume
- 2.37M
Price performance
INSM price history
1M range · 20 trading sessions · Daily adjusted prices
INSM closed at $118.54 after 20 trading sessions, up 20.41% for the selected period.
- Last close
- $118.54
- Period change
- +20.41%
- Period low
- $98.45
- Period high
- $134.75
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $120.11 | $120.66 | $117.15 | $118.54 | 1.98M |
| Aug 27, 2026 | $124.67 | $126.10 | $121.21 | $121.39 | 1.06M |
| Aug 26, 2026 | $122.89 | $125.59 | $121.64 | $124.39 | 1.98M |
| Aug 25, 2026 | $124.65 | $127.18 | $122.865 | $123.89 | 2.37M |
| Aug 24, 2026 | $125.03 | $126.11 | $122.83 | $123.98 | 1.34M |
| Aug 21, 2026 | $125.22 | $127.20 | $124.82 | $125.77 | 1.12M |
| Aug 20, 2026 | $128.36 | $130.27 | $124.60 | $125.08 | 1.76M |
| Aug 19, 2026 | $129.85 | $131.10 | $127.42 | $130.66 | 1.49M |
| Aug 18, 2026 | $128.07 | $128.93 | $126.39 | $128.46 | 1.27M |
| Aug 17, 2026 | $124.71 | $128.46 | $124.6964 | $128.32 | 1.9M |
| Aug 14, 2026 | $125.67 | $126.845 | $122.21 | $123.74 | 1.96M |
| Aug 13, 2026 | $132.50 | $133.16 | $126.13 | $126.33 | 2.48M |
| Aug 12, 2026 | $132.31 | $135.26 | $130.8001 | $132.28 | 1.56M |
| Aug 11, 2026 | $134.55 | $135.30 | $131.67 | $132.57 | 2.73M |
| Aug 10, 2026 | $129.98 | $135.50 | $129.50 | $134.75 | 3.63M |
| Aug 7, 2026 | $134.99 | $135.485 | $126.44 | $131.10 | 4.9M |
| Aug 6, 2026 | $128.22 | $137.70 | $126.15 | $132.55 | 12.04M |
| Aug 5, 2026 | $99.16 | $100.95 | $98.64 | $99.02 | 4.9M |
| Aug 4, 2026 | $98.975 | $99.48 | $97.86 | $98.75 | 4.29M |
| Aug 3, 2026 | $98.20 | $99.9999 | $96.42 | $98.45 | 3.55M |
Latest INSM news
The latest Smart Investors Daily articles mentioning INSM.
Stock researchCompany · Overview
INSM research
Overview
Company profile and research snapshot.
Company profile
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $226.67
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Truist Securities | Buy | — |
| Aug 10, 2026 | JP Morgan | Overweight | — |
| Aug 7, 2026 | Evercore ISI Group | Outperform | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
| Aug 7, 2026 | Wells Fargo | Overweight | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Mar 26, 2026
Liquidia: Yutrepia Has Impressed, But Here's Why I Remain Cautious (Rating Upgrade)
Yutrepia's initial commercialization impresses, but mounting competitive threats cloud long-term prospects for Liquidia. See why LQDA stock is upgraded to hold.
SeekingAlpha · Mar 25, 2026
Insmed Incorporated (INSM) Shareholder/Analyst Call - Slideshow
2026-03-25. The following slide deck was published by Insmed Incorporated in conjunction with this event.
Yahoo · Mar 25, 2026
Insmed CEO reveals Japan patient population exceeds US market for lung disease
Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM) and its lung disease franchise: Japan has more patients with MAC lung disease than the entire United States. That came directly from CEO Will Lewis in a recent interview. “There are actually more patients in Japan that have this disease than there ... Insmed CEO reveals Japan patient population exceeds US market for lung disease
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
